Our Research
Our research team are working with Clinicans in the Northern Ireland Regional Scoliosis Service to help patients and healthcare professionals make decisions about treatment based on the best available research evidence, finding out which treatments work best for young people with scoliosis.
Up to 41% of stroke survivors have some form of cognitive impairment following a stroke, putting them at greater risk of poor psychological wellbeing. These impairments, such as memory and concentration problems, and aphasia result in many stroke survivors being absent from psychosocial research.
Trials of psychological interventions generally exclude people with significant cognitive impairment because of the cognitive demands associated with the intervention techniques and the collection of patient-reported outcome data. Our research team has identified, following the MRC Framework, a psychological approach - Acceptance and Commitment Therapy (ACT) - which shows promise for stroke survivors with significant cognitive impairment. We have also identified a range of modifications and supports which can be incorporated into the ACT protocol to tailor it for the needs of people with cognitive impairments. It is important that this intervention is optimised and shown to be feasible for use in practice prior to investment in a large scale controlled trial.
This project is optimising the intervention via an iterative process involving:
- stakeholder workshops to gather feedback on the intervention and materials, using simulated patient cases to define patient eligibility criteria, and refinement of a logic model describing the implementation of the intervention in practice, and
- a survey and interviews to collect data from patients and carers who will provide feedback on the acceptability and feasibility of the proposed intervention.
Child dental caries remains a significant problem in the UK, with high prevalence in deprived communities. The aim of the trial is to evaluate the effectiveness and cost-effectiveness in NHS primary care of DR-BNI and usual care versus usual care alone, to prevent dental caries in children.
Find out more
Our research project, led by Dr Lisa Graham-Wisener, School of Psychology and Dr Tracey McConnell, School of Nursing and Midwifery, aims to identify where more research is needed for supporting informal carers of people at the end of life. We also invite informal carers to join our Carer Advisory Group (CAG) to work with music therapists and researchers in designing music therapy support during pre-bereavement, that can be used as part of routine NHS care.
Chronic pain is one of the leading causes of impaired functioning and quality of life globally. A key to treatment is to aid those with chronic pain to rebuild effective functioning and re-establish meaningful activity. Professor Vowles is one of the world’s leading clinical researchers in the area of chronic pain (e.g., ScholarGPS identified him as the 7th most highly ranked scholar in terms of lifetime contribution; link) and his work is cited by the National Institute for Health and Care Excellence (NICE, 2021) and the American Psychological Association (link) in their recommendations for chronic pain treatment.
Ongoing work in this area has included the establishment of regional centres for chronic pain rehabilitation, including the Belfast Centre for Pain Rehabilitation (BCPR) at the Belfast City Hospital (service website). The BCPR began during the Covid pandemic and has successfully offered a pain education programme (‘Pain Retrained’) to over 500 patients which are being analysed as part of a PhD trainee in Professor Vowles’ lab, Maura McCarron. The BCPR has also run more than ten three-week intensive pain rehabilitation programmes for individuals with highly complex and disabling chronic pain. This latter programme is the first of its kind on the island of Ireland and is achieving outcomes fully consistent with the established evidence base. Data collection of outcomes through one year follow-up is in progress.
There is also work ongoing with the newly established Paediatric Complex Pain Service with Children’s Health Ireland. This service is the only pain rehabilitation service for under 18’s in Ireland and will run the island’s first ever intensive pain rehabilitation programme for youth with chronic pain in the Autumn of 2024. Professor Vowles has advised the service since its inception and his work has been supported through a grant from the Children’s Health Foundation for developing intensive interdisciplinary pain rehabilitation.
Recently, he published several papers relevant to this topic including a comparative meta-analysis of unidisciplinary and interdisciplinary pain rehabilitation (Vowles et al., 2020), assessment measure revision based on the latest statistical approaches such as Item Response Theory (Vowles et al., 2024), as well as consensus statements on how pain rehabilitation fits with the European Pain Federation’s research strategy (Fullen et al., under review [submitted 23 August 2024]).
Professor Vowles is also an Investigator in a recently funded trial that will identify specific treatment mechanisms influencing the outcomes following behavioural treatments for chronic pain. This trial is pre-registered (NCT02133976) and the study protocol is under review as of summer 2024 (Burns et al., under review). This trial is due to conclude in 2029.
When chronic pain co-occurs with harmful substance use, there is substantial risk of harm. For example, the exponential increase in opioid prescriptions for the treatment of chronic pain over the past few decades has been associated with similar exponential increases in opioid-related harm, such as overdose, diagnoses of opioid use disorder, distress, and disability. Professor Vowles’ work in this area has indicated that harmful patterns of prescribed opioid use in people with chronic pain occurs in a clinically significant minority. His 2015 review of this area has been cited over 900 times in the scientific literature and has been used to inform policy documents for a number of governments across the globe (e.g., SagePolicyProfile), as well as helping to form the foundation for relevant portions of the European Pain Federation’s clinical practice recommendations, which were based on the work of a taskforce co-chaired by Professor Vowles.
Based on his work in the area of co-occurring chronic pain and harmful opioid use, Professor Vowles and colleagues developed an integrated behavioural intervention for co-morbid chronic pain and harmful opioid use. The funded pilot evaluation (pre-registered: NCT02423772) indicated the intervention was feasible, associated with excellent retention in treatment (exceeding 80%), and strong treatment effects in terms of reducing both pain’s interference on functioning and risk of opioid misuse (Vowles et al., 2020). Based on the pilot trial, a fully powered trial was funded in 2019 and will continue through 2025. That trial will recruit individuals with co-morbid chronic pain and opioid use disorder and randomize them to the integrated treatment or an active pain education control condition. Details of the trial were pre-registered (NCT04648228) and the trial protocol has been published (Vowles et al., 2023). Data collection was completed in July of 2024 and the final cohorts of participants will be in the twelve-month follow-up period through summer of 2025. It is anticipated that data analysis complete by the end of 2025.
Professor Vowles’ colleagues have also begun a funded trial of the same integrated treatment to individuals presenting to a specialist addiction treatment service. That trial is also pre-registered (NCT05571917) and the trial protocol is published (Hurlocker et al., 2024). This trial is due to conclude in 2028.
Other work in this area has included evaluations of co-morbid chronic pain, harmful opioid use, and alcohol use disorder (Edwards et al., 2022, Vowles et al., 2022, Witkiewitz and Vowles, 2023).
Chronic non-communicable diseases (NCD), such as diabetes, cardiovascular disease, cancer, and chronic pain, are the leading causes of morbidity and mortality worldwide. The World Health Organization (WHO) notes that NCDs constitute seven of the top ten causes of death and that they are also the leading causes of persisting disability (WHO, 2020). The cost of these conditions is significant – they account for 75% to 90% of healthcare expenditures in developed nations and are involved in half of all General Practitioner appointments in the United Kingdom (UK; Department of Health [DoH], 2012). Chronic NCD’s are a primary contributor to rising healthcare costs and it is predicted that these costs will continue to increase unless pragmatic and implementable solutions are identified to reduce incidence and impact.
Professor Vowles was one of 44 recipients of a UK wide UKRI-funded fellowship (Press Release link). His fellowship entails working within the Northern Ireland DoH to aid in the use of research data in policy work to develop an integrated care pathway for NCDs from community through to speciality care. This fellowship is specifically to evaluate the role of pharmacist independent prescribing in this care pathway. As part of this fellowship, which is funded through early 2025, Professor Vowles has worked with the DoH Chief Pharmaceutical Officer, Professor Cathy Harrison, and her team to determine where the evidence supports pharmacist independent prescribing in NCD and to draft policy documentation for consideration by the Northern Ireland Assembly.
References
Department of Health (2012). Long-term conditions compendium of Information: 3rd edition.
Accessed 5 April 2023. Available at: https://www.gov.uk/government/publications/long-term-conditions-compendium-of-information-third-edition.
World Health Organization (2020). WHO reveals leading causes of death and disability worldwide: 2000-2019. Accessed 13 April 2023. Available at: https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019
Reviews have shown Overdose Prevention Centres can improve health outcomes and address social care needs of people who inject drugs. These facilities provide supervised substance use with sterile equipment, expert advice, and access to essential health and social care services. The UK Advisory Council for the Misuse of Drugs and the Faculty of Public Health, supported by 70+ organizations, recommend establishing OPCs to combat the public health crisis of overdose deaths and reduce drug-related harm. While OPCs have demonstrated success and cost-effectiveness globally, developing UK-specific evaluation tools and service models is crucial for integration with the existing health and social care system.
Aim of overall research programme: This research aims to provide the tools for a comprehensive evaluation of UK pilot OPCs, informing evidence-based implementation strategies, and maximizing potential impact on public health.
We will determine:
- Understanding how overdose prevention centres (OPCs) work and who they work for? Using RAMESES guidelines, we'll conduct a realist review to determine what works, for whom, and under what circumstances in OPCs.
- What should we measure to find out if overdose prevention centres work? Following COMET Initiative guidance, we'll establish essential metrics for OPC evaluation (Core Outcome Set) through evidence review, international e-Delphi with stakeholders, and consensus meetings.
- Impact and Cost-Effectiveness Modelling: We'll develop an epidemiological and economic framework to assess target groups, effects, costs, and cost-effectiveness of OPCs in UK localities.
- UK Health and Social Care Integration: Through interviews with key stakeholders, we'll explore what model might work, how to optimize OPC integration within the existing UK healthcare landscape, ensuring maximum use, cost-savings, and alignment with service user needs.
Research Team: Dr Gillian Shorter & Professor Alex Stevens (Co-Principal Investigators), Professor Peter Vickerman (Co-Applicant), Dr Zarnie Khadjesari (Co-Applicant); Mat Southwell (Co-Applicant); Tanya Telling (Host), Ben Scher (Research Fellow), Dr Adelina Artenie (Research Fellow), Dr Jolie Keemink (Research Fellow); Andrew Dyer (Research Fellow), Lynn Jefferys (Advisor)
Partner institutions: Sussex Partnership NHS Foundation Trust, University of Kent, Queen’s University Belfast, University of Bristol, University of East Anglia, Coact, EuroNPUD
Funder: This study was funded by the National Institute for Health and Care Research (NIHR) [Programme Development Grant (NIHR 204582)]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Selected Outputs:
Report: Want to know more about drug consumption rooms, overdose prevention centres, or safe consumption facilities? See the evidence, common misconceptions, community views, do they work, how they work, and more.
Journal article: Overdose prevention centres as spaces of safety, trust and inclusion: A causal pathway based on a realist review
Talks: at the United Nations Commission for Narcotic Drugs by invitation of Permanent Mission of Greece in Vienna and Permanent Mission of Portugal in Vienna; Stockholm University amongst others
Press: Overdose Prevention Centres have key role in tackling UK drug-deaths crisis, says new research featured in the Guardian, Independent, BBC Radio, HOPE Podcast, Korinthos News, Drink and Drugs News, Sky News, Belfast Live, Belfast Telegraph, BNN, Irish Examiner, View Digital, The National, Glasgow Times, BBC Sounds, PA, News Letter, Irish News, Frontline Podcast